Search

Displaying results 1851 - 1860 of 3015 in total
  1. Drug

    Edoxaban

    go.drugbank.com/drugs/DB09075
    ApprovedInvestigational

    In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will

  2. Drug

    Anthralin

    go.drugbank.com/drugs/DB11157
    Approved

    Anthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago.

  3. Drug

    Bardoxolone methyl

    go.drugbank.com/drugs/DB05983
    Investigational

  4. Drug

    Clavulanic acid

    go.drugbank.com/drugs/DB00766
    ApprovedInvestigationalVet approved

    Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with Amoxicillin or Ticarcillin to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible ...

    Mixtures: Amoxicillin/Clavulansäure Astro 500 mg/100 mg Pulver zur Herstellung einer Injektions- oder Infusionslösung, Amoxicillin/Clavulansäure Astro 1000 mg/200 mg Pulver zur Herstellung einer Injektions- oder Infusionslösung
  5. Drug

    Panitumumab

    go.drugbank.com/drugs/DB01269
    ApprovedInvestigational

    Panitumumab was granted FDA approval on 27 September 2006.[L17663]

  6. Drug

    Brodalumab

    go.drugbank.com/drugs/DB11776
    ApprovedInvestigational

    Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.

  7. Drug

    Diiodohydroxyquinoline

    go.drugbank.com/drugs/DB09115
    Approved

    Iodoquinol is not currently available in any FDA-approved products.

  8. Drug

    Piflufolastat F 18

    go.drugbank.com/drugs/DB14805
    ApprovedInvestigational

    It was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences.

  9. Drug

    Afimoxifene

    go.drugbank.com/drugs/DB04468
    Investigational

    Afimoxifene (4-Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of estrogen-dependent conditions, including cyclic breast pain and gynecomastia. TamoGel is formulated using Enhanced Hydr...

  10. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test. … [A235174] On May 28, 2021, the FDA granted accelerated approval to infigratinib - under the market name Truseltiq - for the treatment of previously treated, unresectable locally advanced or metastatic